Health Economics Letter
THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS
Article first published online: 21 MAY 2013
Copyright © 2013 John Wiley & Sons, Ltd.
Volume 23, Issue 5, pages 621–630, May 2014
How to Cite
Vandoros, S. (2014), THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS. Health Econ., 23: 621–630. doi: 10.1002/hec.2935
- Issue published online: 2 APR 2014
- Article first published online: 21 MAY 2013
- Manuscript Accepted: 10 APR 2013
- Manuscript Revised: 10 MAR 2013
- Manuscript Received: 17 MAY 2011
- patent expiry;
- therapeutic competition;
This paper examines whether there is a switch in total (originator and generic) consumption after generic entry from molecules that face generic competition towards other molecules of the same class, which are still in-patent. Data from six European countries for the time period 1991 to 2006 are used to study the cases of angiotensin-converting enzyme inhibitors and proton pump inhibitors. Empirical evidence shows that patent expiry of captopril and enalapril led to a switch in total (off-patent originator and generic) consumption towards other in-patent angiotensin-converting enzyme inhibitors, whereas patent expiry of omeprazole led to a switch in consumption towards other proton pump inhibitors. This phenomenon makes generic policies ineffective and results in an increase in pharmaceutical expenditure due to the absence of generic alternatives in the market of in-patent molecules. Copyright © 2013 John Wiley & Sons, Ltd.